利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

78 条记录 (耗时 0.022 秒)

    Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor
    1.
    发明申请
    Novel Pharmaceutical Modified Release Dosage Form Cyclooxygenase Enzyme Inhibitor 审中-公开
    新型药物改性释放剂型环氧合酶抑制剂

    公开(公告)号：US20100204333A1

    公开(公告)日：2010-08-12

    申请号：US11988860

    申请日：2006-07-19

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Munish Talwar

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Munish Talwar

    IPC分类号： A61K31/18 ,  A61P25/00 ,  A61P25/06

    CPC分类号： A61K9/2018 ,  A61K9/2027 ,  A61K9/2054 ,  A61K9/2059 ,  A61K9/209 ,  A61K9/4808 ,  A61K9/4858 ,  A61K9/4866 ,  A61K9/5084 ,  A61K31/18 ,  A61K31/192 ,  A61K31/415

    摘要： Pharmaceutical modified release dosage form comprising at least one cyclooxygenase enzyme inhibitor or its pharmaceutically acceptable salts, esters, prodrugs, solvates, hydrates, or derivatives thereof as active agent, with a pharmaceutically acceptable carrier for controlling the release of the cyclooxygenase enzyme inhibitor is provided. The dosage form preferably provides a release of not more than about 60% of the cyclooxygenase enzyme inhibitor in 1 hour and not less than about 75% of the cyclooxygenase enzyme inhibitor after 12 hours when tested in accordance with the dissolution method (I) described herein employing Distilled water with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (II) described herein employing pH 7.0 Phosphate buffer with 2.0% Sodium lauryl sulphate as the dissolution medium or in accordance with the dissolution method (III) described herein employing 0.001 N Hydrochloric acid with 1.0% Sodium lauryl sulphate as dissolution medium. Further, the pharmaceutical composition of the present invention when tested in a group of healthy humans preferably achieves a mean peak plasma concentration (Cmax) after at least about 1 hour of administration of the dosage form. The present invention also provides process of preparing such dosage form compositions and prophylactic and/or therapeutic methods of using such dosage form.

    摘要翻译： 提供了包含至少一种环加氧酶酶抑制剂或其药学上可接受的盐，酯，前药，溶剂化物或其衍生物作为活性剂的药物改性释放剂型，以及用于控制环加氧酶抑制剂释放的药学上可接受的载体。 根据本文所述的溶解方法（I）测试时，剂型优选在12小时后提供不超过约60％的环氧合酶抑制剂的释放量，并且不少于约75％的环氧合酶抑制剂。 使用2.0％十二烷基硫酸钠作为溶解介质的蒸馏水或根据本文所述的溶解方法（II），使用pH 7.0的磷酸盐缓冲液，含有2.0％十二烷基硫酸钠作为溶解介质，或根据溶解方法（III） 本文使用0.001N盐酸与1.0％十二烷基硫酸钠作为溶解介质。 此外，当在一组健康人中测试时，本发明的药物组合物优选在施用剂型至少约1小时后达到平均峰值血浆浓度（C max）。 本发明还提供了制备这种剂型组合物的方法和使用这种剂型的预防和/或治疗方法。

    ANTIBIOTIC COMPOSITIONS OF MODIFIED RELEASE AND PROCESS OF PRODUCTION THEREOF
    2.
    发明申请
    ANTIBIOTIC COMPOSITIONS OF MODIFIED RELEASE AND PROCESS OF PRODUCTION THEREOF 审中-公开
    改性释放物的抗生素组合物及其生产方法

    公开(公告)号：US20090111788A1

    公开(公告)日：2009-04-30

    申请号：US12294353

    申请日：2007-03-07

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Munish Talwar

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Munish Talwar

    IPC分类号： A61K31/43 ,  A61K31/431 ,  A61K31/545 ,  A61K31/426 ,  A61K31/5383 ,  A61P11/00 ,  A61P31/04

    CPC分类号： A61K9/5026 ,  A61K9/284 ,  A61K9/286 ,  A61K9/2866 ,  A61K9/4866 ,  A61K9/4891 ,  A61K9/5047 ,  A61K31/424 ,  A61K31/43

    摘要： Novel modified release pharmaceutical compositions wherein the composition comprises at least one antibiotic(s) preferably amoxicillin or its pharmaceutically acceptable salts, esters, polymorphs, isomers, prodrugs, solvates, hydrates, or derivatives thereof either alone or in combination with other antibiotic(s) as active ingredient, with at least one release modifying agent(s) for controlling the release of the beta lactam antibiotic optionally with one or more other pharmaceutically acceptable excipient(s) is provided, wherein the dosage form provides a release of not more than about 60% of the antibiotic in about 30 minutes and not less than about 70% of the antibiotic after 8 hours when subjected to in vitro dissolution study or when tested in vivo. Further, the compositions of the present invention which when tested in a group of healthy humans provide a mean peak plasma concentration (Cmax) after at least about 0.5 hour of administration of the dosage form. The present invention also provides process of preparing such dosage form and methods of using such dosage form.

    摘要翻译： 新型改性释放药物组合物，其中组合物单独或与其它抗生素组合包含至少一种抗生素，优选阿莫西林或其药学上可接受的盐，酯，多晶型物，异构体，前药，溶剂合物，水合物或衍生物， 作为活性成分，提供了至少一种用于控制任选与一种或多种其它药学上可接受的赋形剂释放β-内酰胺抗生素的释放调节剂，其中该剂型提供不超过约 在进行体外溶出研究或体内测试后8小时后，约30分钟内有60％的抗生素和不少于约70％的抗生素。 此外，当在一组健康人中测试时，本发明的组合物在施用剂型至少约0.5小时后提供平均峰值血浆浓度（C max）。 本发明还提供了制备这种剂型的方法和使用这种剂型的方法。

    Pharmaceutical compositions comprising an extract of Euphorbia prostrata
    3.
    发明授权
    Pharmaceutical compositions comprising an extract of Euphorbia prostrata 有权
    包含大戟提取物的药物组合物

    公开(公告)号：US07371412B2

    公开(公告)日：2008-05-13

    申请号：US10551797

    申请日：2004-12-31

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Aniruddha Datta

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh ,  Aniruddha Datta

    IPC分类号： A61K36/00

    CPC分类号： A61K36/47 ,  A61K36/185 ,  A61K36/48 ,  A61K2300/00

    摘要： The invention relates to novel compositions comprising of an extract of the plant Euphorbia prostrata, particularly with pharmaceutically acceptable carrier(s)/base(s), optionally with additional therapeutic agent(s) useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, inflammatory bowel disease, and the like. The novel compositions possess properties to control inflammation, prevent capillary bleeding and fragility in mammalians, particularly human beings. Process for the preparation of such novel compositions comprising an extract of the plant Euphorbia prostrata and pharmaceutically acceptable carrier(s)/base(s) useful for the treatment of anorectal disease including hemorrhoids, and colonic diseases are also provided. The composition comprise of flavonoidal and phenolic constituents extracted from the plant Euphorbia prostrata that possess anti-inflammatory, analgesic, haemostatic and wound-healing properties.

    摘要翻译： 本发明涉及包含植物大戟提取物，特别是与药学上可接受的载体/碱的提取物的新型组合物，任选地可用于治疗肛门直肠疾病和结肠疾病的其它治疗剂，例如 痔疮，裂缝，裂缝，瘘，脓肿，炎症性肠病等。 该新型组合物具有控制哺乳动物，特别是人类的炎症，防止毛细血管出血和脆性的性质。 还提供了制备这种新型组合物的方法，该组合物包含植物大戟草提取物和可用于治疗包括痔疮和结肠疾病在内的肛门直肠疾病的药学上可接受的载体/碱基。 该组合物包含从具有抗炎，镇痛，止血和伤口愈合特性的植物大戟科提取的黄酮和酚成分。

    Compositions Comprising Glycosaminoglycan and Nonsteroidal Anti-Inflammatory Drug
    6.
    发明申请
    Compositions Comprising Glycosaminoglycan and Nonsteroidal Anti-Inflammatory Drug 审中-公开
    包含糖胺聚糖和非甾体抗炎药的组合物

    公开(公告)号：US20080261866A1

    公开(公告)日：2008-10-23

    申请号：US10586544

    申请日：2005-01-19

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh

    IPC分类号： A61K38/00 ,  A61K31/715 ,  A61P1/00

    CPC分类号： A61K31/726 ,  A61K9/205 ,  A61K9/2054 ,  A61K9/2866 ,  A61K9/4866 ,  A61K31/18 ,  A61K31/196 ,  A61K31/405 ,  A61K31/727 ,  A61K31/728 ,  A61K2300/00

    摘要： Pharmaceutical compositions comprising of glycosaminoglycan or salts thereof, preferably chondroitin or salts thereof, more preferably chondroitin sulphate, and nonsteroidal anti-inflammatory drug(s) or salts thereof, optionally with pharmaceutically acceptable excipient(s) are described. The compositions of the present invention provide gastrosparing effect in conditions where nonsteroidal anti-inflammatory drug(s) or their salts are used, particularly in mammals. Also provided are process for the manufacture of such novel compositions and method to minimize the nonsteroidal anti-inflammatory drug(s) induced gastric toxicity.

    摘要翻译： 描述了包含糖胺聚糖或其盐的药物组合物，优选软骨素或其盐，更优选硫酸软骨素，以及任选具有药学上可接受的赋形剂的非甾体抗炎药或其盐。 本发明的组合物在使用非甾族抗炎药或其盐的条件下，特别是在哺乳动物中提供胃镜效应。 还提供了制备这种新型组合物和方法以使非甾体抗炎药物诱导的胃毒性最小化的方法。

    Pharmaceutical Compositions Comprising Higher Primary Aliphatic Alcohols and Hmg Coa Reductase Inhibitor and Process of Preparation Thereof
    7.
    发明申请
    Pharmaceutical Compositions Comprising Higher Primary Aliphatic Alcohols and Hmg Coa Reductase Inhibitor and Process of Preparation Thereof 审中-公开
    包含高级初级脂肪醇和Hmg Coa还原酶抑制剂的药物组合物及其制备方法

    公开(公告)号：US20080247962A1

    公开(公告)日：2008-10-09

    申请号：US10586545

    申请日：2005-01-19

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh

    IPC分类号： A61K9/12 ,  A61K31/045 ,  A61K31/40 ,  A61P3/00 ,  A61K31/351

    CPC分类号： A61K31/366 ,  A61K31/045 ,  A61K31/40 ,  A61K45/06 ,  A61K2300/00

    摘要： A novel pharmaceutical composition comprising a mixture of higher primary aliphatic alcohols from (24) to (39) carbon atoms; at least one another component selected from resins and pigments, hydrocarbons, esters, ketones and aldehydes, and phenolic compounds, and HMG CoA reductase inhibitor, its salts, analogs or derivatives thereof, preferably statins, optionally with pharmaceutically acceptable excipients, and process of preparation of such composition is provided. Also provided are method of treatment and use of such composition for reducing abnormal lipid parameters associated with hyperlipidemia.

    摘要翻译： 一种新型药物组合物，其包含来自（24）至（39）个碳原子的较高级脂族醇的混合物; 选自树脂和颜料，烃，酯，酮和醛中的至少一种组分和酚类化合物，和HMG CoA还原酶抑制剂，其盐，类似物或衍生物，优选他汀类，任选地具有药学上可接受的赋形剂，以及制备方法 提供了这种组合物。 还提供了治疗和使用这种组合物以减少与高脂血症相关的异常脂质参数的方法。

    Controlled release pharmaceutical compositions
    8.
    发明申请
    Controlled release pharmaceutical compositions 审中-公开
    控释药物组合物

    公开(公告)号：US20090088415A1

    公开(公告)日：2009-04-02

    申请号：US11482185

    申请日：2006-07-06

    申请人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh

    发明人： Rajesh Jain ,  Kour Chand Jindal ,  Sukhjeet Singh

    IPC分类号： A61K31/545 ,  A61K31/43 ,  A61K31/455

    CPC分类号： A61K9/209 ,  A61K9/2018 ,  A61K9/2027 ,  A61K9/2072

    摘要： A non-disintegrating, non-eroding, non-bioadhesive and non-swelling oral controlled release pharmaceutical composition and process for preparation of such compositions is provided which comprises at least one high dose water soluble active ingredient, at least one diluent, at least one binder, and a polymer system comprising of at least one release controlling polymer wherein the composition formulated into a suitable dosage form maintains its geometric shape even after the drug has diffused from the dosage form and provides the concentrations of active ingredient above effective levels for extended periods of time, optionally with other pharmaceutically acceptable excipients. The compositions preferably comprise antibiotic(s) as active ingredient, more preferably Amoxicillin or its pharmaceutically acceptable salts, hydrates, polymorphs, esters, and derivatives thereof, most preferably amoxicillin sodium, either alone or in combination with other antibiotic(s). Also described are controlled release compositions which provide an initial burst release of approximately 20%-40% of the active ingredient within one hour for achieving blood levels equivalent to minimum inhibitory concentration, while maintaining these levels for an extended period of time.

    摘要翻译： 提供了非崩解，非侵蚀，非生物粘附和非膨胀的口服控释药物组合物和用于制备这种组合物的方法，其包含至少一种高剂量水溶性活性成分，至少一种稀释剂，至少一种 粘合剂和包含至少一种释放控制聚合物的聚合物体系，其中配制成合适剂型的组合物即使在药物从剂型扩散后也保持其几何形状，并且将活性成分的浓度提供高于有效水平的时间段 任选地与其它药学上可接受的赋形剂。 组合物优选包含抗生素作为活性成分，更优选阿莫西林或其药学上可接受的盐，水合物，多晶型物，酯和衍生物，最优选阿莫西林钠，单独或与其它抗生素组合。 还描述了控制释放组合物，其在一小时内提供约20％-40％活性成分的初始爆发释放，以达到相当于最小抑制浓度的血液水平，同时将这些水平保持较长时间。

    NOVEL LOW DOSE PHARMACEUTICAL COMPOSITIONS COMPRISING NIMESULIDE, PREPARATION AND USE THEREOF
    10.
    发明申请
    NOVEL LOW DOSE PHARMACEUTICAL COMPOSITIONS COMPRISING NIMESULIDE, PREPARATION AND USE THEREOF 审中-公开
    包含NIMESULIDE的新型低剂量药物组合物，其制备和使用

    公开(公告)号：US20090258947A1

    公开(公告)日：2009-10-15

    申请号：US12298054

    申请日：2007-04-23

    申请人： Rajesh Jain ,  Kour Chand Jindal

    发明人： Rajesh Jain ,  Kour Chand Jindal

    IPC分类号： A61K31/16 ,  A61P25/00

    CPC分类号： A61K31/18 ,  A61K9/0019 ,  A61K9/0095 ,  A61K9/2018 ,  A61K9/2846 ,  A61K9/2866 ,  A61K9/485 ,  A61K9/4858

    摘要： Low dose pharmaceutical dosage form comprising nimesulide or its pharmaceutically acceptable salts, esters, solvates or hydrates thereof, along with one or more pharmaceutically acceptable excipient(s) are provided. The present invention also provides process of preparing such dosage forms and therapeutic methods of using such dosage forms. The low dose compositions 10 are designed to exhibit such bioavailability, which is effective in the treatment of NSAID indicated disorders particularly, which require long-term treatment regimens such as arthritis. Such compositions reduce the cost of therapy in diseases, which require long-term therapies, are easy to manufacture, and also result in the reduction of dose related side effects associated with nimesulide therapy.

    摘要翻译： 提供了包含尼美舒利或其药学上可接受的盐，酯，溶剂化物或其水合物以及一种或多种药学上可接受的赋形剂的低剂量药物剂型。 本发明还提供了制备这种剂型的方法和使用这种剂型的治疗方法。 低剂量组合物10被设计为表现出这样的生物利用度，其在治疗特别是需要长期治疗方案例如关节炎的NSAID指征的病症中是有效的。 这样的组合物降低了需要长期疗法，易于制备的疾病的治疗成本，并且还导致与尼美舒利治疗相关的剂量相关的副作用的减少。